Introduction
============

Uveitis is a term used to describe a group of intraocular inflammatory diseases that can occur at any age but that disproportionately affects patients in the working age group resulting in serious impact on their individual lives and on the society as a whole.[@b1-opth-9-1655],[@b2-opth-9-1655] It is a relatively uncommon condition with an estimated incidence of 17.4--52.4 cases per 100,000 person-years and a prevalence of 58.0--114.5 per 100,000 persons.[@b3-opth-9-1655]--[@b7-opth-9-1655] It causes 2.8%--10% of legal blindness in the United States or nearly 30,000 new cases of blindness each year.[@b4-opth-9-1655]

Although uveitis is a well-known cause of blindness, there is only limited knowledge concerning the prevalence and incidence of uveitis among the blind. In most epidemiological studies dealing with blindness, uveitis is not considered a distinct entity.[@b8-opth-9-1655]--[@b10-opth-9-1655] Previous clinical studies confirm a significant rate of visual impairment due to numerous causes, including cataract, glaucoma, and cystoid macular edema.[@b2-opth-9-1655],[@b11-opth-9-1655]--[@b13-opth-9-1655] The aims of this retrospective, obser vational study were to investigate the degree and causes of visual loss in uveitis patients in relation to the development of complications while undergoing treatment.

Methods
=======

Patient selection
-----------------

This was a retrospective observational study of all patients seen in the eye clinic at the University of Virginia, between 1984 and 2014. The study received institutional review board approval. Patient consent was not required as this is a retrospective chart review. An electronic chart review was performed on 1,238 patients with uveitis identified by International Classification of Disease, 9th revision codes corresponding to ocular inflammatory conditions. Individual charts were reviewed and 747 patients were excluded because a diagnosis of uveitis meeting International Uveitis Study Group[@b14-opth-9-1655],[@b15-opth-9-1655] criteria could not be confirmed by an attending physician (AKR). A further 33 patients (40 eyes) were excluded from the clinical outcome analysis component of the study because no follow-up visit information was available. The total number of patients included in the study was 491 (644 eyes). After excluding 33 patients (40 eyes), best-corrected visual acuity (BCVA) and intraocular pressure (IOP) analysis was done for 458 patients (604 eyes) as the initial and final data was available for this subset of patients only.

Data collection
---------------

For every patient, information was gathered regarding demographic details as well as disease anatomic classification according to the Standardization of Uveitis Nomenclature Working Group criteria, which was categorized as either anterior uveitis (AU) or non-AU (intermediate uveitis, posterior uveitis, and panuveitis),[@b15-opth-9-1655] laterality, cause, and concomitant systemic diseases. We recorded BCVA, IOP, and clinical examination findings for the initial and final visits. The BCVA results were converted to logMAR units for analysis.[@b16-opth-9-1655],[@b17-opth-9-1655] Mild or no visual loss (MdVL) was defined as \>20/50 on Snellen chart (logMAR \<0.4), moderate visual loss (MVL) as 20/50--20/200 (logMAR 0.4 to \<1.0), and severe visual loss (SVL) as \<20/200 (logMAR ≥1.0).[@b15-opth-9-1655] World Health Organization (WHO) definition of blindness (from no light perception to 20/400 logMAR \>1.3) was taken into consideration.[@b18-opth-9-1655] Ocular hypertension was defined as an IOP \>21 mmHg and hypotension as IOP ≤7 mmHg.[@b19-opth-9-1655],[@b20-opth-9-1655]

Optical coherence tomography, fluorescein angiography, automated perimetry, and other ancillary tests including serology, radiology, microbiology, and biopsy were performed when appropriate. Intraocular infection was confirmed with fluid sampling or biopsy for microscopy and cytology and culture or polymerase chain reaction, when clinically appropriate. Postprocedural uveitis was defined as ocular inflammation following intraocular surgery, laser, or intravitreal injection. The term "undifferentiated uveitis" was applied if intraocular inflammation could not be attributed to a recognized uveitic entity.

Details of management including the use of local and systemic steroids, intravitreal injections, subtenon injections, antimetabolites, anti-tumor necrosis factor agents, cataract surgery, pars plana vitrectomy (PPV), and glaucoma management (medical and surgical intervention) were recorded. Finally, we collected information regarding burden of disease, including number of clinic visits.

In general, treatment decisions were based on the presence of ocular inflammation as well as associated problems, such as increased IOP and cystoid macular edema. The use of systemic steroids and the addition of second-line immunosuppressive or biologic agents were decided according to clinical judgment of disease activity. Local treatment, using periocular and intravitreal steroid injections was used to reduce the need for systemic drugs and their related side effects.

Statistical analysis
====================

Descriptive statistics
----------------------

Continuous scaled data were either summarized by the mean and standard deviation of the empirical distribution, or summarized by the median and interquartile range \[IQR\] of the empirical distribution. Categorical scaled data were summarized by frequencies and percentages.

Visual outcomes
---------------

BCVA in logMAR at baseline and last-follow-up were compared by way of paired permutation tests, in which the null hypothesis was that the underlying distribution for the baseline to last-follow-up change in logMAR was equal to zero.[@b21-opth-9-1655] A two sided *P*≤0.05 decision rule was utilized as the null hypothesis rejection criterion.

McNemar tests were used to compare within each baseline vision loss category (ie, MdVL, MVL, and SVL), the percentage of eyes that were in each category at baseline to the percentage of eyes at last follow-up. A two sided *P*≤0.05 decision rule was utilized as the null hypothesis rejection criterion.

Quantile regression was used to compare the linear trajectories for median logMAR between AU and non-AU subgroups.[@b22-opth-9-1655] Since several patients had bilateral uveitis, the regression analyses were conducted at the patient level. The logMAR for bilateral uveitis cases represented the average logMAR of the two affected eyes.

A binomial multivariate generalized estimating equation model[@b23-opth-9-1655] was utilized to examine the relationship between categories of vision loss (MdVL, MVL, and SVL) at last follow-up and underlying factors predictive of visual morbidity in uveitis. These factors included: patient age at diagnosis, patient gender, race, uveitis laterality (unilateral vs bilateral), baseline vision classification (ie, logMAR \<0.40, logMAR \[0.40 to \<1\], and logMAR ≥1.0), follow-up duration (years), and uveitis location (ie, anterior, intermediate, posterior, or panuveitis), and systemic involvement (ie, yes vs no). Bilateral case outcomes were not assumed to be statistically independent and to account for this nonindependence between outcomes the variance covariance matrix of the generalized estimating equation model was estimated via the working independence sandwich estimator.[@b21-opth-9-1655] Hypothesis testing was based on the Type III Wald statistic, and a two-sided *P*≤0.05 decision rule was utilized as the null hypothesis rejection criterion.

IOP outcomes
------------

McNemar tests were conducted to compare the baseline and follow-up frequencies of ocular hypertension and hypotony. A two-sided *P*≤0.05 decision rule was utilized as the null hypothesis rejection criterion.

Treatment differences between AU and non-AU groups
--------------------------------------------------

AU vs non-AU comparisons of medication and surgery requirements were based on the Fisher's exact test. A two-sided *P*≤0.05 decision rule was utilized as the null hypothesis rejection criterion for all tests.

Statistical software
--------------------

The software of SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) and the software of Spotfire S+ (TIBCO Software Inc., Palo Alto, CA, USA) were used to conduct the aforementioned statistical analyses.

Results
=======

Four-hundred and ninety one patients (644 eyes) were included in this study. A total of 278 (56.6%) patients were females with female: male ratio of 1.3:1. Mean duration of follow-up was 4.8 years (±6.8). Mean number of visits to the eye clinic was 11 (±14.3). Of the 491 patients, 338 (68.8%) had unilateral disease. Of the 491 patients, 57 (11.6%) had documentation of acute onset, and 158 (32.8%) had insidious onset. A total of 276 (56.2%) patients had chronic uveitis. Clinical (BCVA, IOP) outcomes were analyzed for only those 458 patients and 604 eyes for whom initial and final BCVA and IOP data were available.

Patient demographics
--------------------

### Age

Different age groups with MdVL, MVL, and SVL at presentation and at the end of the study are given in [Table 1](#t1-opth-9-1655){ref-type="table"}. Overall, the mean age at presentation was 45.5±21.3 years (range 0.5--110.6 years), while the mean age at diagnosis was 46.0±21.4 years (range 0.5--110.6 years). Only 4 (0.8%) patients were more than 100 years of age. For those patients who had BCVA measured at diagnosis (n=480), the mean age at diagnosis was 43.3±20.3 years for the cohort of patient who had MdVL at presentation (n=280) and 48.7±21.9 years for the cohort of patient who had MVL at presentation (n=85) and 51.2±23.2 years for the cohort of patients who had SVL at presentation (n=115). Again, the cohort of patients who had MdVL at presentation was somewhat younger than the cohort of subjects with MVL (*P*=0.059) and SVL (*P*=0.002) at presentation.

### Gender

There were 278 female patients (56.6%). Within the MdVL cohort, there were 167 (59.6%), while within the MVL cohort there were 46 (54.1%) female patients, and within the SVL cohort there were 54 (50.9%) female patients. Females were more likely to have MdVL at presentation than to have SVL at presentation, where the converse was true for males (*P*=0.025). Baseline characteristics of the uveitis patient at the time of diagnosis are presented in [Table 2](#t2-opth-9-1655){ref-type="table"}.

### Follow-up

The median length of follow-up was 2.0 years (IQR: 0.2--6.8 years, range 0--30 years, mean 4.8 years), 1,948 patient-years and 2,475 eye-years. Sixty-six eyes (16.2%) had more than 10 years follow-up, and the median follow-up for those eyes was 15.7 years with range 10.2--30 years.

### Visual outcome

With respect to the entire group of uveitis patients (n=458; 604 eyes) who had BCVA assessed at baseline and then at last follow-up, the median BCVA at the time of diagnosis was 0.18 logMAR (IQR: 0.10--0.60 logMAR), and the final median BCVA at the end of the study was 0.18 logMAR (IQR: 0.0--0.48 logMAR).

At baseline (n=604 eyes), there were 400 (66.2%) eyes from 322 patients (70.3%) with MdVL (20/40 or better, \<0.4 logMAR), 62 eyes (10.3%) from 56 patients (13.5%) with MVL (20/40--20/200, logMAR 0.4--1), and 142 eyes (23.5%) from 133 patients (29.0%) with SVL (20/200 logMAR 1.0 or worse). At the end of the study (n=604 eyes), there were 444 (73.5%) eyes from 351 (76.6%) patients with MdVL, 69 (11.4%) eyes from 64 (10.6%) patients with MVL, and 91 (15.0%) eyes from 87 (14.4%) patients with SVL. Of the 400 eyes with MdVL at presentation, 15 (3.7%) eyes progressed to MVL by last-follow-up while 35 (8.7%) eyes progressed to SVL. Of the 62 eyes with MVL at diagnosis, 43 (69.4%) improved to MdVL by last-follow-up, while 11 (17.7%) eyes progressed to SVL. Of the 142 eyes with SVL at diagnosis, 51 (35.9%) eyes improved to MdVL by last-follow-up, while 10 (7.0%) eyes improved to MVL. A tabular summary of the visual outcome information is provided in [Table 3](#t3-opth-9-1655){ref-type="table"}, with additional information pertaining BCVA within the three vision loss subgroups, and the baseline to follow-up changes in BCVA are graphically presented in [Figure 1](#f1-opth-9-1655){ref-type="fig"}. At the end of the study, a total of 73 (12.1%) eyes met WHO criteria for blindness. Twenty-two patients had bilateral blindness.

### Vision stability: AU vs non-AU

Eye level analyses revealed that at the time of diagnosis, median logMAR was 0.18 (95% CI: \[0.14, 0.21 logMAR\]) for the AU patients and 0.30 units (95% CI: \[0.22, 0.38 log-MAR\]) for the non-AU patients (*P*=0.008). The predicted median logMAR trajectories for AU and non-AU eyes are displayed in [Figure 2](#f2-opth-9-1655){ref-type="fig"}. For AU eyes, the follow-up trajectory for median logMAR was 0.007 logMAR units/year (95% CI: \[0.000, 0.013 logMAR/year\], *P*=0.034), while for the non-AU patients, the follow-up trajectory for median logMAR was 0.004 logMAR units/year (95% CI: \[−0.000, 0.015 logMAR/year\], *P*=0.064). The median trajectories were not statistically different between the two groups (*P*=0.877).

Patient level analyses revealed that at the time of diagnosis, median logMAR was 0.18 (95% CI: \[0.13, 0.23 logMAR\]) for the AU patients and 0.48 units (95% CI: \[0.38, 0.57 logMAR\]) for the non-AU patients (*P*\<0.001). For AU patients, the follow-up trajectory for median logMAR was 0.008 logMAR units/year (95% CI: \[−0.000, 0.017 logMAR/year\], *P*=0.066), while for the non-AU patients, the follow-up trajectory for median logMAR was 0.004 logMAR units/year (95% CI: \[−0.014, 0.023 logMAR/year\], *P*=0.636). The median trajectories were not statistically different between the two groups.

Eyes with AU (n=386) vs eyes with non-AU (n=223) were no more likely to have MVL (11.9% vs 10.3% respectively, *P*=0.571). Eyes with AU, however, were less likely (10.6% vs 22.4%, respectively) to have SVL (odds ratio 2.43; 95% CI: \[1.52, 3.89\], *P*\<0.001).

### Diagnosis

The anatomical classification for the cohort is given in [Table 4](#t4-opth-9-1655){ref-type="table"}.

The relative frequencies of key uveitis diagnoses and the number of eyes with MdVL, MVL, and SVL at the end of study are given in [Table 5](#t5-opth-9-1655){ref-type="table"}.

### Factors predictive of visual morbidity in uveitis

Multivariate analyses showed that for the 500 eyes that had complete baseline demographics and diagnostic information, neither age at uveitis diagnosis (*P*=0.089), nor gender (*P*=0.264), nor race (*P*=0.144) were predictors of MVL or SVL at last follow-up. Similarly, neither follow-up duration (*P*=0.675), nor uveitis laterality status (*P*=0.359) were predictors of MVL or SVL at last follow-up. The location of uveitis at diagnosis was also not a predictor of MVL or SVL at last follow-up (*P*=0.359), nor was systemic involvement (*P*=0.371). However, vision loss at diagnosis was a predictor for MVL or SVL at last follow-up (*P*\<0.001). Eyes that had MVL at the time of uveitis diagnosis were more likely (odds ratio 3.05; 95% CI: \[1.50, 6.16\]) to have MVL to SVL at follow-up than eyes that had MdVL at uveitis diagnosis (*P*=0.002). Eyes that had SVL at the time of uveitis diagnosis, were considerably more likely (odds ratio 9.57, 95% CI: \[5.73, 15.96\], *P*\<0.001) to have MVL to SVL at last follow-up than eyes with MdVL at uveitis diagnosis. Eyes that had SVL at the time of uveitis diagnosis, were also considerably more likely (odds ratio 3.14, 95% CI: \[1.53, 6.46\], *P*=0.002) than eyes with MVL at diagnosis to have MVL to SVL at last follow-up.

### IOP

Of the 644 eyes from 491 patients, 618 (96.0%) eyes from 471 patients had baseline IOP recorded. Median initial IOP was 15.0 mmHg (IQR: 12, 18 mmHg). Seventy-six (12.3%) eyes from 68 patients presented with ocular hypertension at baseline. Six-hundred and five (93.4%) eyes from 459 patients had IOP assessed at last follow-up. Median final IOP was 14.0 mmHg (IQR: 12--18 mmHg). Forty-seven (7.8%) eyes from 46 patients had ocular hypertension at follow-up.

At both the baseline and the follow-up assessments, ocular hypertension was positively associated with MVL and SVL while hypotony was not. If an eye was hypertensive at the baseline assessment, the odds that the eye had MVL to SVL was 1.89 times (95% CI: \[1.15, 3.11\]) than the odds for an eye that was normotensive (*P*=0.012). If an eye was hypertensive at follow-up, the odds that the eye had MVL to SVL was 2.62 time (95% CI: \[1.38, 4.98\], *P*=0.003) than the odds for an eye that was normotensive.

### Treatment of uveitis, complications and interventions

Management of uveitis patients is documented in [Table 6](#t6-opth-9-1655){ref-type="table"}.

### Treatment differences between AU and non-AU

There was no significant difference in the median annual number of clinical visits between AU and non-AU patients (median 6; IQR: 3--13 vs median 6; IQR: 3--15, respectively, *P*=1.000).

Fewer patients with AU (66/329, 20.1%) were treated with oral prednisone (*P*\<0.001) than those with non-AU (67/159, 42.1%). More AU patients (274/331, 82.8%) received local steroid injections (*P*\<0.001) than patients with non-AU (91/158, 57.6%). The prescription of second-line agents was similar between AU patients (10/330, 3.0%) and non-AU patients (7/159, 4.4%) (*P*=0.439).

AU and non-AU patients experiencing MVL to SVL were compared to patients not experiencing MVL to SVL. Among AU patients, those who experienced MVL to SVL were not likely to receive systemic corticosteroids than those who did not experience MVL or SVL (20/79 \[25.3%\] vs 33/233 \[18.9%\], respectively, *P*=0.259). AU patients who experienced MVL to SVL were also no more likely to receive a second-line therapeutic agent than those who did not experience MVL to SVL (3/80 \[3.7%\] vs 7/233 \[3.0%\], respectively, *P*=0.720). AU patients, who experienced MVL to SVL, however, were more likely to have cataract or glaucoma surgery than those who did not experience MVL to SVL (38/80 \[52.5%\] vs 54/179 \[23.2%\], respectively, *P*\<0.001), or to have PPV (11/80 \[1.37%\] vs 5/228 \[2.1%\], respectively, *P*\<0.002).

Among non-AU patients, those who experienced MVL to SVL were not likely to receive systemic corticosteroids than those who did not experience MVL to SVL (27/66 \[40.9%\] vs 32/82 \[39.0%\], respectively, *P*=0.867). Non-AU patients who experience MVL to SVL were also not likely to receive a second line therapeutic agent than those who did experience MVL to SVL (2/66 \[3.0%\] vs 5/82 \[6.1%\], respectively, *P*=0.468). Non-AU patients, who experience MVL to SVL, were not likely to have cataract or glaucoma surgery than those who did experience MVL to SVL (16/66 \[24.2%\] vs 22/82 \[26.8%\], respectively, *P*=0.856), but more likely to have PPV (20/66 \[30.3%\] vs 7/82 \[8.5%\], respectively, *P*=0.001).

Discussion
==========

Several factors affect the progress and the outcomes of uveitis. The primary focus of this study was to evaluate the visual and clinical outcomes of uveitis over a period of 30 years.

The average age of diagnosis was 46 years which is comparable to the range reported in other studies (46.1--48 years).[@b12-opth-9-1655],[@b13-opth-9-1655],[@b24-opth-9-1655] Patients with SVL at presentation were significantly older than those with MdVL to MVL. A similar observation has been reported previously.[@b13-opth-9-1655],[@b25-opth-9-1655] This is probably related to an increasing prevalence of panuveitis and bilateral disease with increasing age, though Darrell et al did not find age to be a risk factor.[@b6-opth-9-1655] Tomkins-Netzer et al reported that uveitis occurs in young patients.[@b2-opth-9-1655] Most of the patients included in our analysis were in the working age group as well. Mean duration of follow-up for our study was 4.8 years which is much longer than reported in other studies.[@b12-opth-9-1655],[@b13-opth-9-1655] Overall, we had more female patients (56.6%), which has been reported in earlier studies (57.8%--62%).[@b13-opth-9-1655],[@b24-opth-9-1655],[@b26-opth-9-1655] As these studies and ours is based on patients from a tertiary referral service, it raises the possibility that women are more susceptible to severe uveitis than men. One of the studies reported that the age of onset of uveitis and patient gender were not found to have a statistically significant impact on vision.[@b2-opth-9-1655] Interestingly, female patients in our study had lower rate of SVL at presentation. It is possible for women being more inclined to seek medical attention than men. This has not been reported elsewhere to our knowledge.

Durrani et al reported that patients with bilateral intraocular inflammation, panuveitis, Asian origin, and increasing age had a poorer visual prognosis.[@b13-opth-9-1655] Tomkins-Netzer et al confirmed increased risk for visual loss in patients with non-AU disease, vitreous opacities, retinal detachment, cystoid macular edema, macular scarring, macular hole, optic neuropathy, or macular ischemia.[@b2-opth-9-1655] The multivariate analysis of our study did not support age, gender, ethnic origin, location, laterality of the disease, and follow-up duration as predictors of visual loss. However, we observed that SVL at baseline was significantly associated with MVL to SVL at the end of the study. This would imply the need for early diagnosis and appropriate management.

In our study, 14.4% of eyes experienced SVL \<20/200 and 70.1% had visual acuity \>20/40 at the end of the study. Though, this visual loss is in accordance with the earlier report by Durrani et al it is higher than reported in other studies.[@b2-opth-9-1655],[@b13-opth-9-1655] The overall average visual acuity remained stable over our study period. Approximately 70% of eyes achieved visual acuity of better than 20/40 and approximately 80% attained visual acuity of better than 20/200. An earlier study reported that average BCVA remained stable throughout follow-up for more than 10 years, with approximately 80% avoiding vision loss. Other studies have shown variable visual outcomes. The percentage of patients avoiding MVL (BCVA \>20/50) ranges from 30% at an average final follow-up of 36.7 months in a study by Durrani et al to 65% at 4.3 years in a study by Rothova et al.[@b11-opth-9-1655],[@b13-opth-9-1655] Bodaghi et al established that at a final average follow-up of 3.5 years, more than 85% of eyes had a BCVA of 20/200 or better.[@b12-opth-9-1655] In a UK cohort of 315 patients, 69.9% experienced visual loss (\<6/18 with 50.45% having bilateral reduced vision) with 72% having severe loss of vision. Their percentage was higher than previously reported,[@b1-opth-9-1655],[@b11-opth-9-1655],[@b27-opth-9-1655] and it may be due to their definition of visual loss (\<6/18).[@b13-opth-9-1655] Most other studies used the WHO definition of vision loss.[@b1-opth-9-1655],[@b11-opth-9-1655],[@b28-opth-9-1655]--[@b30-opth-9-1655] By upholding a stratagem of early treatment decisions and immunosuppression to maintain a state of remission, it is possible to maintain a steady BCVA in most patients.[@b27-opth-9-1655]

The incidence of blindness among patients with uveitis is poorly defined. The incidence of total blindness due to uveitis in the United States was estimated to be 10%--15%.[@b31-opth-9-1655] Seventy three eyes (12.1%) in our study group met WHO criteria for blindness which is close to the one observed by Durrani et al (11.4%).[@b13-opth-9-1655] Twenty-two (4.8%) of our patients developed bilateral blindness. In another series of 582 patients, bilateral legal blindness developed in 22 (4%) patients.[@b11-opth-9-1655] Severe uveitis that is resistant to treatment; uveitis that is not promptly and effectively treated; or uveitis that is accompanied by significant secondary complications may result in poor visual outcomes, including blindness. Despite this, with appropriate modern therapy in informed, cooperative patients, few individuals with uveitis should suffer such devastating outcomes.

In our study, ocular hypertension was associated with MVL and SVL. Of interest, the majority (89.7%) of patients who presented with ocular hypertension at the initiation of the study period were normotensive at the end of the study. Further analysis of ocular hypotony and hypertension as determinants of uveitis outcomes will be revealed in one of our forthcoming papers.

The etiology of uveitis and the anatomical location of uveitis alter the course and the outcome of uveitis. Earlier studies conducted at tertiary referral centers reported that more patients are likely to suffer from bilateral disease and panuveitis.[@b12-opth-9-1655],[@b13-opth-9-1655],[@b26-opth-9-1655] Results from community-based studies report AU as the most common type of uveitis.[@b32-opth-9-1655],[@b33-opth-9-1655] In our cohort, AU was the most common anatomical type observed. None of the anatomical uveitis diagnoses were associated with significant visual loss. Further analysis revealed that visual acuity was significantly different between AU and non-AU groups. Non-AU group presented with worse vision than the AU cohort, which has been reported earlier.[@b2-opth-9-1655]

SVL was more common among patients with pan-uveitis, followed by AU in a few of the previous reports.[@b11-opth-9-1655]--[@b13-opth-9-1655] In this series, the most common cause of SVL was postprocedural uveitis followed by undifferentiated AU, trauma, and undifferentiated panuveitis. This difference in types of uveitis associated with SVL may be explained by different classification criteria employed. Most of the previous papers used anatomical classification,[@b11-opth-9-1655]--[@b13-opth-9-1655] while we reported both anatomical and etiological categories of uveitis.

Common complications of uveitis include glaucoma and cataract, and the management of those complications could be medical or surgical depending on the severity. Rothova et al stated that 23% of their 582 patients required one or more intraocular surgical procedures. The percentage of those requiring surgery increased with the duration of follow-up. The most frequent surgical procedures were cataract extractions, vitrectomy, surgery for glaucoma, and retinal detachment.[@b11-opth-9-1655] Approximately one-third of the eyes in our cohort required ocular surgery, with cataract extraction being the most common procedure. In our observation, cataract and glaucoma surgery was more frequently performed on patients with AU who suffered MVL to SVL, as also reported by Tomkins-Netzer et al.[@b2-opth-9-1655] Although these procedures are considered low-risk for patients without uveitis, uveitis patients face are at increased risk of complications, including intraocular inflammation.[@b34-opth-9-1655]--[@b36-opth-9-1655] It has been recommended that eyes be quiet for at least three months prior to surgery, thus the patient may suffer prolonged visual morbidity until the eye is optimized for surgery.

In this study, almost 75% patients received local and 27% systemic corticosteroids. Fewer patients with AU compared with those with non-AU required systemic corticosteroids but more of them received local corticosteroids. Similar results have been published earlier.[@b2-opth-9-1655] A retrospective study of 834 uveitis cases conducted in Tokyo reported that approximately 60% of patients received topical and/or periocular injections of corticosteroids; and approximately one-fourth (28.6%) of patients required some form of systemic immunomodulatory therapy including corticosteroids.[@b24-opth-9-1655]

Limitations
===========

This review is based on data from a tertiary center and is therefore susceptible to limitations based on referral bias, treatment bias, and retrospective data collection. Moreover, management may have been influenced by health insurance policy, the availability of uveitis specialist, and the treatment preferences of the uveitis specialists involved in the study.

Conclusion
==========

In this series of patients with uveitis, we observed that 1) median BCVA was stable from initial to final visit; 2) poorer visual outcomes were seen in patients with SVL at presentation, non-AU, and ocular hypertension; 3) better visual outcomes were associated in patients with younger age, female gender and AU; 4) approximately two-thirds of patients had no or mild vision loss; 5) approximately one-third of patients required systemic treatment; and 6) less than half of patients required ocular surgery.
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![Change in logMAR at last follow-up from logMAR at baseline (ie, at diagnosis) for the set of eyes that had both baseline and follow-up BCVA assessed (n=604 eyes).\
**Note:** Hatch horizontal line identifies zero change in logMAR.\
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![Quantile regression predictions for patient level median logMAR as a linear function of follow-up time (years).\
**Note:** Solid points identify the predicted median logMAR at the midpoint of the time interval and the "x" symbol identifies the empirical median logMAR for the time interval.\
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###### 

Age groups with MdVL, MVL, and SVL at presentation and at the end of the study

  Assessment               Age group    Number of eyes (ne), n (% overall)   MdVL, n (% within age group)   MVL, n (% within age group)   SVL, n (% within age group)
  ------------------------ ------------ ------------------------------------ ------------------------------ ----------------------------- -----------------------------
  Presentation (ne =633)   \<18         54 (8.5)                             40 (69.0)                      7 (12.1)                      11 (19.0)
  18--35                   161 (25.4)   118 (73.3)                           12 (7.5)                       31 (19.3)                     
  18--65                   448 (70.8)   306 (68.3)                           43 (9.9)                       99 (22.1)                     
  \>65                     126 (20.0)   69 (54.8)                            14 (11.1)                      43 (34.1)                     
  Follow-up (ne =603)      \<18         56 (9.3)                             42 (75.0)                      7 (12.5)                      7 (12.5)
  18--35                   150 (24.9)   128 (85.3)                           8 (5.3)                        14 (9.3)                      
  18--65                   429 (71.1)   330 (76.9)                           42 (9.8)                       57 (13.3)                     
  \>65                     123 (20.4)   76 (61.3)                            20 (16.3)                      27 (22.0)                     

**Notes:** \<18 years: pediatric group; 18--35 years: young adults; 18--65 years: working age group; \>65 years: older age group.

**Abbreviations:** MdVL, mild visual loss; MVL, moderate visual loss; SVL, severe visual loss.

###### 

Baseline characteristics of the uveitis patient at the time of diagnosis

                                                                      Number (%)
  ------------------------------------------------------------------- ----------------
  **Patient level baseline characteristics**                          
  Number of patients (n)                                              491
  Female gender                                                       278 (56.6)
  Mean age (SD), years                                                45.5 (21.5)
  Race                                                                
   Asian                                                              5 (1.0)
   African American                                                   134 (27.3)
   Caucasian                                                          298 (60.7)
   Hispanic                                                           12 (2.4)
   Other                                                              42 (8.5)
  Systemic involvement                                                335 (68.2)
  Bilateral vision reported (n=491)                                   153 (31.2)
  Vision loss (n=481)                                                 
   MdVL (logMAR: \<0.4)                                               280 (58.2)
   MVL (logMAR: \[0.4--1\])                                           85 (17.7)
   SVL (logMAR: ≥1)                                                   116 (24.1)
  **Eye level baseline characteristics**                              
  Number of eyes (ne)                                                 644
  Non-anterior uveitis                                                237 (36.8)
  Median length of follow-up (interquartile range) years, (ne =520)   4.8 (0.2--6.8)
  Mean BCVA (SD), logMAR (ne =633)                                    0.52 (0.74)
  Visions loss (ne =633)                                              
   MdVL (logMAR: \<0.4)                                               415 (65.6)
   MVL (logMAR: \[0.4--1\])                                           64 (10.1)
   SVL (logMAR: ≥1)                                                   154 (24.3)
  Mean BCVA overall (SD), logMAR (ne =633)                            0.52 (0.74)
   MdVL, mean BCVA (SD)                                               0.13 (0.13)
   MVL, mean BCVA (SD)                                                0.56 (0.06)
   SVL, mean BCVA (SD)                                                1.56 (0.86)

**Abbreviations:** BCVA, best-corrected visual acuity; logMAR, logarithm of the minimum angle of resolution; SD, the standard deviation of the measurement distribution; MdVL, mild visual loss; MVL, moderate visual loss; SVL, severe visual loss; ne, number of eyes.

###### 

Visual outcomes for the subset of uveitis patients with both baseline and follow-up visual acuity assessments (n=458; 604 eyes)

  Vision group at baseline                                             Baseline assessment   Follow-up assessment   *P*-value[\*](#tfn4-opth-9-1655){ref-type="table-fn"}
  -------------------------------------------------------------------- --------------------- ---------------------- -------------------------------------------------------
  [\*\*](#tfn5-opth-9-1655){ref-type="table-fn"}logMAR, median (IQR)   0.18 (0.10--0.60)     0.18 (0.0--0.48)       1.000
  MdVL, median (IQR)                                                   0.10 (0.00--0.18)     0.10 (0.0--0.30)       1.000
  MVL, median (IQR)                                                    0.48 (0.48--0.60)     0.30 (0.11--0.48)      \<0.001
  SVL, median (IQR)                                                    1.18 (1.00--1.47)     1.00 (0.30--1.30)      \<0.001
  MdVL, ne (%)                                                         400 (66.2)            444 (70.1)             \<0.001
  MVL, ne (%)                                                          62 (10.3)             69 (10.9)              0.468
  SVL, ne (%)                                                          142 (23.5)            91 (14.4)              \<0.001

**Notes:**

*P*-value based on a permutation test, where the null hypothesis was that the difference between the baseline and the follow-up median logMAR is simply a consequence of chance;

all visual loss cohorts combined.

**Abbreviations:** logMAR, logarithm of the minimum angle of resolution; MdVL, mild visual loss; MVL, moderate visual loss; ne, number of eyes; SVL, severe visual loss.

###### 

Anatomical classification (n=491, 644 eyes)

  Classification          Number of patients (%)   Number of patients with bilateral disease (%)   Number of patients with unilateral disease (%)
  ----------------------- ------------------------ ----------------------------------------------- ------------------------------------------------
  Anterior uveitis        332 (67.6)               75 (22.6)                                       257 (77.4)
  Non-anterior uveitis                                                                             
   Intermediate uveitis   26 (5.3)                 19 (73.1)                                       7 (26.9)
   Posterior uveitis      62 (12.6)                32 (51.6)                                       30 (48.4)
   Panuveitis             71 (19.5)                27 (38.0)                                       44 (62.0)

###### 

Diagnostic uveitis classification for MdVL, MVL, SVL for those eyes that had both initial and final BCVA available (n=458; 604 eyes)

  Visual loss (number of eyes \[ne\])   Diagnosis             Number of eyes[\*](#tfn7-opth-9-1655){ref-type="table-fn"} (%)
  ------------------------------------- --------------------- ----------------------------------------------------------------
  MdVL (ne=444)                         Trauma                48 (10.8)
  Sarcoidosis                           34 (7.7)              
  AU-HLAB27                             34 (7.7)              
  MVL (ne=69)                           AU-undifferentiated   20 (29.0)
  Sarcoidosis                           10 (14.5)             
  Postprocedural                        6 (8.7)               
  SVL (ne=91)                           Postprocedural        16 (17.6)
  AU-undifferentiated                   12 (13.2)             
  Trauma                                7 (7.7)               
  Sarcoidosis                           7 (7.7)               
  Panuveitis-undifferentiated           7 (7.7)               

**Note:**

Percentages are for each group of disease severity and not for the entire study population.

**Abbreviations:** AU, anterior uveitis; BCVA, best-corrected visual acuity; HLAB27, human leucocyte antigen B27; MdVL, mild visual loss; MVL, moderate visual loss; SVL, severe visual loss.

###### 

Ophthalmic management and interventions

  Treatment/intervention       Number of patients (%)
  ---------------------------- ------------------------
  Local steroids               365 (74.6)
  Systemic steroids            133 (27.3)
  Anti-TNFα agents             17 (3.5)
  Antimetabolites              52 (10.6)
  Intravitreal injection       54 (11.0)
  Subtenon injection           23 (4.7)
  Glaucoma topical treatment   116 (23.6)
  Glaucoma surgery             43 (8.8)
  Cataract surgery             129 (26.4)
  Pars plana vitrectomy        46 (9.4)

**Abbreviation:** TNFα, tumor necrosis factor alpha.
